ADICT - Bispecific Antibody Platform with Optimization of Action Mechanism and Target Combination

By virtue of our comprehensive understanding of the tumor microenvironment, immune cells, and mechanisms of therapeutic targets, we have developed in-house ADICT (Antibody-Directed-Immune Cell-Activation at Tumor Site) technology platform for the development of first-in-class bispecific antibodies with novel combinations and mechanisms.

Cytotoxic T or NK cell redirection

4-1BB (CD137) is a co-stimulatory receptor widely expressed in activated T cells and natural killer cells （NK） and other immune cells.

T cell co-stimulatory signals mediated by 4-1BB can enhance the proliferation, cytotoxicity, and cytokine secretion of related immune cells, and protect them from activation-induced cell death (AICD).
Effective and moderate tumor immune activation

4-1BB is highly expressed in CD8+ tumor infiltrating lymphocytes (TILs), and CD8+ TILs expressing 4-1BB are also considered tumor-reactive T cells.

4-1BB can effectively activate TILs and promote the generation of memory T cells, in terms of tumor specific T cells.
Targeted delivery and enrichment of cytokines

Systemic administration of cytokines usually has high toxicity. Targeted delivery and enrichment of cytokines can enhance their anti-tumor efficacy while reducing toxicity.